| Drug | Class | Adult | Paediatric | Notes |
|---|---|---|---|---|
| N-acetylcysteine (NAC)[1] | Glutathione precursor | 150 mg/kg IV over 1 h, then 50 mg/kg over 4 h, then 100 mg/kg over 16 h (21-h regimen, may extend) | Same per kg | Paracetamol-induced ALF (definitive). Also used in non-paracetamol ALF (improves transplant-free survival per Lee 2009) |
| Lactulose + rifaximin (encephalopathy)[1] | Ammonia-lowering combination | Lactulose 30–45 mL PO/NG TDS titrated to 2–3 soft stools/day; rifaximin 550 mg PO BD | Per weight | Hepatic encephalopathy in ALF; rifaximin reduces recurrence |
| Hypertonic saline or mannitol (cerebral oedema)[1] | Osmotherapy | 3% saline to target Na 145–155 mmol/L; mannitol 0.5–1 g/kg IV bolus | — | Grade III–IV encephalopathy with cerebral oedema; consider ICP monitoring in selected cases |
| Glucose infusion (hypoglycaemia prevention)[1] | IV dextrose | 10% dextrose infusion to maintain glucose >70 mg/dL; serial glucose monitoring | — | Hypoglycaemia common in ALF due to depleted hepatic gluconeogenesis |
| Vitamin K[1] | Coagulation factor cofactor | 10 mg IV daily × 3 days | — | Correct any vitamin K deficiency contributing to coagulopathy; does NOT correct synthetic dysfunction in ALF |
Recognition and management of acute liver failure — coagulopathy + encephalopathy in patients without prior liver disease; transplant evaluation is time-critical.